aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
From TechCrunch
By Robert Frawley
May 27, 2024
The countdown to early-bird savings for TechCrunch Disrupt, taking place October 28–30 in San Francisco, continues. You have just five days left to save up to $800 on the price of admission. The window closes on Friday, May 31 at 11:59 p.m. PDT. Grab your tickets today.
Disrupt is where you’ll find innovation for every stage of your startup journey. Whether you’re a budding founder with a revolutionary idea, a seasoned startup looking to scale, or an investor seeking the next big thing, Disrupt offers unparalleled resources, connections, and expert insights to propel your venture forward. Join 10,000 tech leaders for three startup-packed days in San Francisco this October.
Share:
Retro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan
OpenAI CEO Sam Altman is doubling down on Retro Biosciences, a biotech startup based in San Francisco that wants humans to live 10 years longer than what it calls a healthy human lifespan. Altman previously provided Retro Biosciences’ entire seed round of $180 million. Now, the startup is raising a $1 billion Series A that Altman is joining, The Financial Times reports. Retro Biosciences, which says it plans to launch trials for drugs targeting diseases like Alzheimer’s, recently trained a mode
Jan 24, 2025
TechCrunch Disrupt 2025 tickets now on sale: Lowest rates ever
We’re kicking things off earlier than ever! TechCrunch Disrupt 2025 tickets are officially on sale. Don’t miss your chance to snag them at the lowest rates of the year! Immerse yourself in the epicenter of tech innovation at Disrupt 2025! From October 27 to 29, Moscone West in San Francisco transforms into the global hub for technology and venture capital. Experience 250+ powerful sessions, 200+ expert-led discussions, the thrilling Startup Battlefield 200, and unparalleled networking with 10,0
Jan 24, 2025
Neko Health’s unicorn-sized Series B is larger than some Series C rounds
Welcome to Startups Weekly — your weekly recap of everything you can’t miss from the world of startups. Want it in your inbox every Friday? Sign up here. This week was supposed to be a short one in the U.S., as it started with a holiday. But Inauguration Day kept some founders busy, and the following days brought us more than their fair share of startup news. Most interesting startup stories from the week Image Credits:David Paul Morris/Bloomberg via Getty This week reminded us that not all sal
Jan 24, 2025
Don't miss our latest news and updates. Subscribe to the newsletter